Gesellschaft Fuer Epilepsieforschung — Clinical Trial Site

24 Registered trials

15 Currently recruiting

Organisation

Gesellschaft Fuer Epilepsieforschung

Location

Bielefeld, Germany

Identifier

ORG-100042320

Address

Maraweg 21, Gadderbaum, 33617, Germany

Departments

#0902: Pediatric and adolescent epileptology
#303_00270267: Krankenhaus Mara, Epilepsie-Zentrum
#40685; Epilepsiezentrum Bethel
#40685: Epilepsiezentrum Bethel
Department for Epileptology
Department of Epileptology
Department of General Epileptology, Bethel Epilepsy Center
Epilepsie-Zentrum Bethel
Epilepsieambulanz
Epilepsiezentrum Bethel
Epileptology
Krankenhaus Mara
Krankenhaus Mara – Epilepsiezentrum Bethel
N/A
Neurology

Clinical trials at this site (24)

Search interface

A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting

2025-524038-24-00 Focal Epilepsy 5 2026-05-22
EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting

2024-519555-28-00 Dravet syndrome 5 2026-03-18
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
A study to learn how safe fenfluramine is, how well it works, and how it moves through the bloodstream in infants with Dravet syndrome Recruiting

2022-502359-75-00 Dravet syndrome 5 2024-07-03
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Primary Generalized Tonic-Clonic Seizures 5 2023-10-27
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy. Recruiting

2025-521640-38-00 Focal onset seizures or primary generalized tonic-cloni 5 2025-10-16
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting

2024-514937-39-00 Dravet Syndrome 5 2025-05-20
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508811-21-00 Refractory Focal Onset Epilepsy 10 2024-09-25
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Ope… Recruiting

2023-509672-42-00 GRIN-related neurodevelopmental disorder 5 2023-02-02
An extension study to learn if Staccato Alprazolam is safe when treating long seizures in children ≥12 years of age and adults Recruiting

2023-508868-30-00 Treatment of stereotypical prolonged seizure 5 2022-09-26
An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult… Recruiting

2024-510950-29-00 Stereotypical prolonged seizure 5 2022-07-21
A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Ended

2024-516412-17-00 Developmental and Epileptic Encephalopathies (DEE) 5 2025-08-26
A Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Ended

2023-506269-78-00 CDKL5 Deficiency disorder 5 2023-06-20
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep… Ended

2023-508681-15-00 Adult focal (partial onset) epilepsy 4 2019-05-28
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic… Ended

2024-517061-16-01 Focal onset seizures or primary generalized tonic-cloni 4 2025-02-27
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN… Ended

2023-508812-45-00 Idiopathic Generalized Epilepsy with Generalized Tonic- 10 2024-11-11
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep… Ended

2022-503067-15-00 Tuberous Sclerosis Complex (TSC) related epilepsy 5 2023-10-02
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended

2022-502802-34-00 Dravet and Lennox-Gastaut Syndromes 5 2022-04-05
The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in… Expired

2022-501028-95-00 focal (partial onset) epilepsy 4